top of page
Dr. Bobojon Nazarov

MSc (Oxon), PhD (Oxon), MBA (Oxon)

  • LinkedIn
Dr. Bobojon Nazarov

MSc (Oxon), PhD (Oxon), MBA (Oxon)

Born in Central Asia, Bobojon moved to the UK at the age of 13. From a young age his father, a physicist, nurtured within Bobojon a love for the sciences. On arriving in the UK, despite speaking almost no English, Bobojon sat school entrance exams and scored 98% on his physics paper. It was Chemistry, however, that captured his imagination and ultimately led him to read a PhD in Chemical Biology at the University of Oxford.


As a firm believer in systems approaches, Bobojon encourages all his students to explore a broad range of subjects in order to identify their true passion. Thus, in his role as an educator, he believes in nurturing a students' budding interest to facilitate their growth.








University of Oxford, Corpus Christi College

MBA, Pershing Square Scholar (fully funded scholarship with stipend)

University of Oxford, Corpus Christi College

D.Phil. (Ph.D.) in Chemical Biology, EPSRC Scholar (fully funded scholarship with stipend)

University of Oxford, Somerville College

MSc in Pharmacology

University of Bristol

MSc in Economics, Finance & Management 

University of Bristol

BSc (Hons) in Pharmacology - 2.1

Is your child feeling lost and unmotivated, and you are having difficulty helping them regain their passion for education or reach specific goals? If so, I can assist you in this matter because I focus on empowering students by restoring their self-confidence, uncovering their talents, and helping them take control of their path to success. 

My love for the sciences was unlocked at a young age, which equipped me with various toolkits to tackle challenges beyond exams and education. I sharpened my teaching skills during my postgraduate studies at the University of Oxford; I taught subjects ranging from Economics to Natural Sciences, from prep school to postgraduate levels. This was when I began noticing how critical it was for students to have a sense of direction.

I am also the founder of a biotech company, Latus Therapeutics, which focuses on oncology and autoimmune diseases but is currently concentrating on completing the Phase 2 trials for therapeutic agents in COVID-19.

If you're interested in collaborating, please get in touch with me using the email address above. Kindly understand that I can only train a limited number of students at a time because of my work commitments and focus on achieving results. Therefore, please don't take it personally if I cannot assist you on this occasion.

Work Experience









Latus Therapeutics, Founder, Oncology Biotech Start-up

  • Originated and launched two clinical trials that recognised the functional importance of TMPRSS2 in priming SARS-CoV-2 for entering a host cell

    • SPIKE-2: partnered with the University of Edinburgh for nafamostat trial

    • SPIKE-1: sub-contracted CRUK as a trial sponsor for camostat trial

  • Raised £1.2m from LifeArc, led and executed the overall strategy of the SPIKE trials

  • Principal Investigator for the NCT04455815 clinical trial in partnership with CRUK

  • Principal Investigator for the NCT04473053 clinical trial in partnership with the University of Edinburgh

Daten Capital, Fund Manager, Biotech AI Hedge Fund

  • Invested in 34 trials with an accuracy of 82% in predicting primary endpoint outcomes

  • Responsible for setting the investment strategy, fundraising, and investment decisions

  • Built a team of academic advisors and employees with cross-functional expertise from deep scientific knowledge to trading to equity and derivatives valuation

Life Sciences Partners (LSP), Analyst, Long only Biotech Hedge Fund

  • Provided in-depth analytical support to the LSP investment team with a prime focus on LSP’s investment activities in the biotech public equity franchise

Merck Ventures, Analyst

  • Involved in the entire investment process from the initial screening of the deal flow to the selection of investment opportunities

  • Conducted in-depth scientific, clinical due diligence and market research on listed portfolio companies

University of Oxford, Department of Pharmacology, Tutor

  • Taught cell signalling to medical and biomedical students

Oxford Pharmacology Ventures (OPV), President and Founder

  • Founded a club that fosters collaborations between the pharmaceutical industry and Oxford’s Pharmacology Department to take our in-house findings to the market

  • Took part in Europe's Leading Biopartnering and Investment Conference (BioTrinity) from 2012 -2015 to showcase assets from the pharmacology department to venture capital firms and facilitated meetings between academics and industry practitioners

Chicago Mercantile Exchange, Senior Research Analyst

  • Researched and estimated price for spin-offs

  • Built, maintained, and calculated bespoke equity and Dow Jones public indices

  • Researched and applied corporate actions and ran quarterly rebalances

IHS Markit, Equity Analyst:

  • Forecasted dividends for publicly listed European, Russian, and U.S. corporations

  • Built and enhanced dividend forecasting models

  • Built families of ETFs (totalling 1000s ETFs)

  • Used quantitative methods to extensively model derivatives (vanilla and exotic)

  • Produced daily CDS valuations involving yield curve bootstrapping, fitting volatility skews

bottom of page